|
|
|
Amyloid-beta, a protein well known for its role in Alzheimer's disease, may yield its damaging effects on neurons by binding to the cellular prion protein (PrPC), a paper published in Nature suggests. This could make PrPC a potential target for Alzheimer's disease therapeutics.
Misfolded variants of PrPC have been implicated in prion diseases, such as bovine spongiform encephalopathy (BSE), but the normal endogenous version is found in many types of cell. In neurons, PrPC appears to act as a receptor for the amyloid-beta protein, Stephen Strittmatter and colleagues report. Moreover, they show that the deleterious effects of amyloid-beta on long-term potentiation in brain slices, an experimental model for learning and memory, are mediated by PrPC.CONTACT Stephen Strittmatter (Yale University School of Medicine, New Haven, CT, USA)
E-mail: stephen.strittmatter@yale.edu (C) Nature press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|